Abstract
Despite the remarkable clinical results, the autologous nature of CAR-T cell manufacturing process restricts the access of patients to this therapy. Therefore, one of the next frontiers in the field is to develop an allogeneic, 'off-the-shelf', CAR-T cell therapy. Initial studies have already provided a proof-of-concept of such "universal" therapy by knocking out the T cell receptor (TCR)…